AstraZeneca Plc achieved a double-digit increase in revenue in the 2022 first quarter on the back of strong demand for its oncology medicines and $1.7 billion in sales of drugs for rare diseases generated by Alexion Pharmaceuticals, its recent acquisition. AstraZeneca acquired Alexion in July 2021 for $39 billion. However operating profit declined on amortisations related to the Alexion purchase and payments arising from a patent dispute.
